Medtronic Issues IDE to FDA for Randomized Clinical Trial for Uncontrolled Hypertension Patients with Systolic Blood Pressure Between 140-160mm Hg
Posted on March 07, 2013 at 10:02 AM EST
Medtronic, Inc. (NYSE: MDT ), announced today that the company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) to study the Symplicity(TM) renal denervation system for the treatment of uncontrolled hypertension in patients with systolic blood pressure between 140-160 mm Hg despite treatment with three or more